HyperaFRA:HM6A -2.76%92 FCF Yield % is 11.98 as of Jul. 02, 2026, which is 230% above its 10-year median of 3.63. GuruFocus rates FRA:HM6A with a GF Score™ of 92/100 and a GF Value™ of €5.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Hypera ranks better than 91.05% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Hypera's Trailing 12-Month Free Cash Flow is €288 Mil, and Market Cap is €2,478 Mil. Therefore, Hypera's FCF Yield % for today is 11.98%.
The historical rank and industry rank for Hypera's FCF Yield % or its related term are showing as below:
FRA:HM6A'
s FCF Yield % Range Over the Past 10 Years
Min: -4.33 Med: 3.63 Max: 16.68
Current: 11.98
During the past 13 years, the highest FCF Yield % of Hypera was 16.68%. The lowest was -4.33%. And the median was 3.63%.
FRA:HM6A's FCF Yield % is ranked better than 91.05% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.655
vs FRA:HM6A: 11.98
Hypera's FCF Margin % for the quarter that ended in Mar. 2026 was 18.96%.
Hypera FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hypera FCF Yield % Related Terms
Hypera FCF Yield % Historical Data
* Premium members only.
The historical data trend for Hypera's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HM6A vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Hypera's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypera (FRA:HM6A) has a FCF Yield % of 11.98 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hypera and its competitors. This is 230% above median its historical median of 3.63. According to the industry distribution chart, Hypera ranks #90 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Hypera's FCF Yield % too high?
Hypera's current FCF Yield % of 11.98 is 230% above median its 10-year median of 3.63. The Drug Manufacturers industry median FCF Yield % is 0.66. Hypera's value of 11.98 is 1729% above this industry median. Based on the distribution chart, Hypera ranks #90 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hypera has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #90 out of 1006 companies for FCF Yield %. This places Hypera in the top 9% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.66. Hypera's value of 11.98 is 1729% above this benchmark. While the company's 10-year median is 3.63 vs. the industry median of 0.66, Hypera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.66, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current FCF Yield % of 11.98 is 1729% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hypera and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current FCF Yield % is 11.98, which is 230% above median its own 10-year median of 3.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (FRA:HM6A) is currently considered Possible Value Trap. The stock's GF Value™ is €5.23, compared to a current price of €3.52 — trading 32.7% below its estimated fair value. The current FCF Yield % is 11.98, which is 230% above median its 10-year median of 3.63 and 1729% above the Drug Manufacturers industry median of 0.66. Hypera's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Hypera (FRA:HM6A), the current FCF Yield % is 11.98 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (FRA:HM6A) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of €3.52 is trading 32.7% below its estimated GF Value™ of €5.23.
GuruFocus considers Hypera to be Possible Value Trap.
Key valuation signals for FRA:HM6A:
FCF Yield %: 11.98 (230% above median its 10-year median of 3.63)
GF Value™: €5.23 vs. price of €3.52 (32.7% below fair value)
Industry Position: 1729% above the Drug Manufacturers median (#90 of 1006)
No single metric tells the full story. See the FRA:HM6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
92GF Score
Get the complete analysis for FRA:HM6A
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HM6A has been successfully added to your 
